CymaBay Therapeutics, Inc.
DelistedCIK 1042074fmd_06HQ406CYDDZ9WP5Q97DH10ZNMManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2012 to Dec 31, 2023, 46 periods
| Line item | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | 10 | – | – | – | 0 | 0 | 31 |
| Research and development | 16 | 17 | 16 | 19 | 58 | 84 | 36 | 65 | 68 | 81 |
| Total operating expenses | 24 | 26 | 26 | 31 | 73 | 108 | 53 | 88 | 93 | 133 |
| Operating income | (24) | (26) | (26) | (21) | (73) | (108) | (53) | (88) | (93) | (102) |
| Interest expense | 1 | 1 | 1 | 1 | 0 | – | – | 3 | 15 | 19 |
| Interest and investment income | 0 | 0 | 0 | 1 | 4 | 5 | 2 | 0 | 2 | 13 |
| Other non-operating income (expense) | (7) | 11 | (1) | (6) | (0) | 5 | 2 | (2) | (13) | (4) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | (32) | (16) | (27) | (28) | (73) | (103) | (51) | (90) | (106) | (105) |
| Net income to common shareholders | (32) | (16) | (27) | (28) | (73) | (103) | – | – | – | – |